# Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

> **NCT04787744** · PHASE2,PHASE3 · RECRUITING · sponsor: **VA Office of Research and Development** · enrollment: 464 (estimated)

## Conditions studied

- Prostate Cancer
- Oligometastasis
- Oligorecurrence
- Recurrent Prostate Cancer
- Metastatic Prostate Cancer
- De Novo Prostate Cancer

## Interventions

- **PROCEDURE:** PET-directed Local Therapy using Surgery
- **RADIATION:** PET-directed Local Therapy using Radiation
- **OTHER:** Salvage Local Therapy for locally recurrent disease
- **DRUG:** Goserelin, Histrelin, Leuprolide & Triptorelin
- **DRUG:** ADT + Nilutamide, Flutamide, & Bicalutamide
- **DRUG:** Degarelix & Relugolix
- **DRUG:** ADT + Docetaxel +/- prednisone
- **DRUG:** ADT + Abiraterone + Prednisone
- **DRUG:** ADT + Abiraterone + Methylprednisolone
- **DRUG:** ADT + Apalutamide
- **DRUG:** ADT + Enzalutamide
- **RADIATION:** Prostate-directed Radiation for De novo oligometastatic prostate cancer

## Key facts

- **NCT ID:** NCT04787744
- **Lead sponsor:** VA Office of Research and Development
- **Sponsor class:** FED
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-07-01
- **Primary completion:** 2026-09-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 464 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787744, "Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04787744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*